Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic prostate cancer improved overall and failure-free survival, with a small increase in high-grade toxic effects.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 377; číslo 4; s. 338 - 351
Hlavní autoři:	James, Nicholas D, de Bono, Johann S, Spears, Melissa R, Clarke, Noel W, Mason, Malcolm D, Dearnaley, David P, Ritchie, Alastair W.S, Amos, Claire L, Gilson, Clare, Jones, Rob J, Matheson, David, Millman, Robin, Attard, Gerhardt, Chowdhury, Simon, Cross, William R, Gillessen, Silke, Parker, Christopher C, Russell, J. Martin, Berthold, Dominik R, Brawley, Chris, Adab, Fawzi, Aung, San, Birtle, Alison J, Bowen, Jo, Brock, Susannah, Chakraborti, Prabir, Ferguson, Catherine, Gale, Joanna, Gray, Emma, Hingorani, Mohan, Hoskin, Peter J, Lester, Jason F, Malik, Zafar I, McKinna, Fiona, McPhail, Neil, Money-Kyrle, Julian, O’Sullivan, Joe, Parikh, Omi, Protheroe, Andrew, Robinson, Angus, Srihari, Narayanan N, Thomas, Carys, Wagstaff, John, Wylie, James, Zarkar, Anjali, Parmar, Mahesh K.B, Sydes, Matthew R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 27.07.2017
Témata:	Abiraterone Acetate - administration & dosage Abiraterone Acetate - adverse effects Adult Aged Aged, 80 and over Androgen Antagonists - administration & dosage Androgen Antagonists - adverse effects Androgens Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Clinical trials Death Endocrine therapy Hormone replacement therapy Humans Male Medical prognosis Medical research Mens health Metastases Metastasis Middle Aged Neoplasm Metastasis - drug therapy Neoplasm Recurrence, Local - drug therapy Oncology Prednisolone Prednisolone - administration & dosage Prednisolone - adverse effects Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Radiation therapy Steroid 17-alpha-Hydroxylase - antagonists & inhibitors Survival Analysis
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic prostate cancer improved overall and failure-free survival, with a small increase in high-grade toxic effects.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 A complete list of the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators is provided in the Supplementary Appendix, available at NEJM.org. The authors’ full names, academic degrees, and affiliations are listed in the Appendix.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1702900